Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Procaps Group S.A. (PROC)

Procaps Group S.A. (PROC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 304,614
  • Shares Outstanding, K 112,820
  • Annual Sales, $ 409,920 K
  • Annual Income, $ 42,540 K
  • 60-Month Beta 0.13
  • Price/Sales 0.67
  • Price/Cash Flow 4.86
  • Price/Book 7.51
Trade PROC with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.07
  • Growth Rate Est. (year over year) +1,427,042.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.53 +7.11%
on 04/09/24
3.11 -12.72%
on 03/20/24
-0.48 (-15.05%)
since 03/19/24
3-Month
2.53 +7.11%
on 04/09/24
4.38 -38.13%
on 01/24/24
-1.63 (-37.56%)
since 01/19/24
52-Week
1.95 +38.97%
on 10/20/23
5.38 -49.63%
on 04/20/23
-1.83 (-40.31%)
since 04/19/23

Most Recent Stories

More News
Procaps Group Reports Preliminary First Quarter 2022 Results

Net Revenues Increased by 11% to U$ 86 million, with Adjusted EBITDA Up 15% Year-Over-Year to $9 Million...

PROC : 2.71 (+0.37%)
Procaps Group to Acquire Grupo Somar (including Química y Farmacia, Gelcaps and related entities) from Advent International, gaining an important presence in Mexico, the Region's Second Largest Market

This acquisition reaffirms Procaps Groups’ strategy to become one of the fastest growing pharmaceutical organizations in Latin America With FY2021 Net...

PROC : 2.71 (+0.37%)
Procaps Group Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Procaps Group S.A. (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its financial results for the fourth quarter and fiscal year ended...

PROCW : 0.0600 (+9.89%)
PROC : 2.71 (+0.37%)
Procaps Group Announces Capacity Expansion Plans in the United States with Construction of New Gummy Manufacturing Facility in Florida

Procaps Group (NASDAQ: PROC), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced a new capacity expansion plan in the United States and Colombia for its Funtrition...

PROC : 2.71 (+0.37%)
Procaps Group Announces Appointment of Melissa Angelini as Investor Relations Director

Procaps Group (NASDAQ: PROC), a leading integrated international healthcare and pharmaceutical company, today announced the appointment of Melissa Angelini as Investor Relations Director, effective February...

PROC : 2.71 (+0.37%)
Procaps Group Acquires 1st U.S.-Based Softgel Production Facility and Pharmaceutical R&D Center to Expand Global Growth of its iCDMO Business Unit

Procaps Group (NASDAQ: PROC), a leading integrated international healthcare and pharmaceutical company, today announced the closing of an asset purchase agreement to acquire an 86,000 sq. ft. pharmaceutical...

PROC : 2.71 (+0.37%)
Procaps Group Reports Record Third Quarter 2021 Financial Results

Procaps Group (NASDAQ: PROC), a leading integrated international healthcare and pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2021.

PROC : 2.71 (+0.37%)
LATN : 9.86 (+6.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Procaps Group is a developer of pharmaceutical and nutraceutical solutions, medicines and hospital supplies. It develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and high-potency clinical solutions. Procaps Group, formerly known as Union Acquisition Corp....

See More

Key Turning Points

3rd Resistance Point 2.71
2nd Resistance Point 2.71
1st Resistance Point 2.71
Last Price 2.71
1st Support Level 2.71
2nd Support Level 2.71
3rd Support Level 2.71

See More

52-Week High 5.38
Fibonacci 61.8% 4.07
Fibonacci 50% 3.66
Fibonacci 38.2% 3.26
Last Price 2.71
52-Week Low 1.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar